Myhep-Mydekla tablet has two component Sofosbuvir & Daclatasvir Sofosbuvir: Sofosbuvir is a prohibitor of nucleotide analogue, especially prohibits HCV non-structural protein 5B RNA dependent RNA polymerase. Sofosbuvir undergo intracellular metabolism, which produce pharmacologically active compound like uridine analog triphosphate. Sofosbuvir interceded into RNA of hepatitis C virus with the help of NS5B polymerase. This may acts as chain eliminator. Daclatasvir: Non structural 5A protein is essential for viral multiplication. Daclatasvir interfere with the activity of NS5A protein, this may leads to viral eradication.
Brand : Myhep-Mydekla
Ingredients : Sofosbuvir + Daclatasvir Dihydrochloride
Strength : 400mg & 60 mg
Manufactured : Mylan
Package : 28 tablets
Before staring the treatment with Myhep-Mydekla tablet, patient may examine periodically by taking hepatic function test and analysis the lab values. Examine HBV infection by counting hepatitis B surface antigen & hepatitis B core antibody.Dosage recommendation
The usual dose of Myhep-Mydekla tablet is one tablet should be taken as a single dose by administering with food or without food.
On severe condition, Myhep-Mydekla must be combine with ribavirin.
The initial dose of ribavirin is 600mg as a single dose, elevating dose up to 1000mg administrated for In HCV genotype I or III patients
with decompensated cirrhosis or post transplantation.
The initial dose of ribavirin should be calculated on the basis of body weight of the suspected patients having with compensated cirrhosis; In patient with weight of at least 75kg: 1200mg of ribavirin should be considered. In patient with weight of less than 75kg: 1000mg of ribavirin should be used.
The dose of Myhep-Mydekla is one tablet should be taken with or without food as a single dose given for Patient suffered without cirrhosis & compensated cirrhosis: In decompensated cirrhosis or post liver transplantation: The recommended dose of Myhep-Mydekla is one tablet to be taken as a single dose by combining with ribavirin on weight basis manner.In genotype III
Patient struggling without cirrhosis: The usual dose of Myhep-Mydekla is one tablet to be taken as a single dose. : The usual dose is one Myhep-Mydekla tablet should be combined with ribavirin as a single dose is given for Patient with compensated, decompensated cirrhosis or post liver transplantation While receiving ribavirin, patient must be administered food. Ribavirin should be taken as twice daily.
Side effects occurred in Myhep-Mydekla tablet receiving patients such as; Fatigue Headache Insomnia Nausea Pruritus Asthenia Anemia Loss of appetite Flu like syndrome Pyrexia Diarrhea Rash Neutropenia Myalgia Irritability Pancytopenia Increase of creatine kinase, bilirubin, lipase, AST & ALT HBV reoccurrence may occurs Serious bradycardia while combining with amiodarone
Use with caution in the patients are suspected with HBV infection, there is a chance of increasing the risk of HBV reoccurrence in the patient co infected with HCV & HBV Severe bradycardia occurs while concomitant use of Myhep-Mydekla with amiodarone Exposure of loss of therapeutic effect occurs while concurrently use Myhep-Mydekla tablet with P-gp inducers or inhibitors Severe adverse effects may occur due to drug interaction, to prevent this problem avoid this type of combinational therapy.